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Abstract
Atherosclerosis is a complex, multifactorial disease with both genetic and environmental 
determinants. Experimental investigation of the effects of these determinants on the development 
and progression of atherosclerosis has been greatly facilitated by the use of targeted mouse models 
of the disease, particularly those resulting from the absence of functional genes for apolipoprotein 
E or the low density lipoprotein receptor (LDLR). This review focuses on the influence on 
atherosclerosis of combining apoE or LDLR deficiencies with factors affecting atherogenesis, 
including (1) inflammatory processes, (2) glucose metabolism, (3) blood pressure, and (4) 
coagulation and fibrinolysis. We also discuss the general problem of using the mouse to test the 
effects on atherogenesis of human polymorphic variations and future ways of enhancing the 
usefulness of these mouse models.
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The Mouse as a Model System for Studying Atherosclerosis
Ten years ago, no strains of mice were available that spontaneously developed complex 
atherosclerotic lesions, although small lesions of the fatty streak type could be induced in 
strain C57BL/6 mice by feeding them high-fat/high-cholesterol diets (see References 1 
through 3). The advent of gene targeting4–6 to modify genes in a predetermined manner 
changed the situation dramatically by allowing the generation of mice having targeted 
inactivation of the apolipoprotein E (Apoe) gene in 19927–9 and of the LDL receptor (Ldlr) 
gene in 1993.10 Both of these animals, under appropriate conditions, develop complex 
atherosclerotic lesions and provide practical atherosclerotic mouse models.11–13
ApoE is an amphipathic protein that plays a pivotal role in lipoprotein trafficking. ApoE is a 
constituent of chylomicrons, VLDL, and HDL and acts as a ligand for the receptor-mediated 
clearance of these particles.14 Mice lacking apoE have plasma cholesterol levels that are 4 
to 5 times normal and develop atherosclerotic lesions spontaneously, even when fed a 
normal chow diet, which is low in fat and cholesterol. The lesions resemble human lesions 
© 2000 American Heart Association, Inc.
Correspondence to Dr Nobuyo Maeda, Department of Pathology and Laboratory Medicine, CB No. 7525, University of North 
Carolina, Chapel Hill, NC 27599-7525. nobuyo@med.unc.edu. 
NIH Public Access
Author Manuscript
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2015 February 09.
Published in final edited form as:






















and progress over time from an initial fatty streak to a complex lesion with a fibrous cap,
15,16 and lesion development can be accelerated by a high-fat, high-cholesterol diet.17 
Mice lacking the LDLR have less overt disease, with a modest 2 times normal plasma 
cholesterol level when maintained on a normal chow diet, and they develop atherosclerosis 
only slowly.18 However, in response to a high-fat, high-cholesterol diet, LDLR-deficient 
mice exhibit massive elevations in plasma cholesterol and rapidly develop atherosclerotic 
lesions throughout the aorta.19 There is much less published data on the kinetics of lesion 
development in LDLR-deficient mice than in apoE-deficient mice. Nevertheless, the lesions 
that develop in Apoe- and Ldlr-deficient mice are generally the same, with the plaques 
developing in a time-dependent manner, starting from the proximal aorta and spreading 
toward the distal aorta, and particularly involving locations where blood flow is disturbed. 
Although the merits of each model and of different methods of assessing the extent of 
atherosclerosis are still debated, results with the 2 models are generally comparable and 
largely independent of whether the quantification is based on the lipid content of the aorta, 
the surface area of lesions in the aortic tree, cross-sectional plaque size in the proximal aorta, 
or cellular composition of plaque materials. The predictable development of plaques in these 
mutants, along with other more general advantages of mice, such as their small size, short 
generation time, and relative ease of care, have quickly made the mouse a very effective and 
practical model for the study of atherosclerosis. However, the most important advantage is 
the availability of genetically defined inbred and mutant strains and the well-established 
means of using these strains to manipulate the mouse genome.
In humans, current evidence suggests that susceptibility to atherosclerosis is most likely due 
to unfavorable combinations of mutations affecting genes in several pathways, but our 
knowledge about which genes are involved is limited.20 Genetic analysis in mice provides a 
powerful approach toward identifying the genes and pathways involved. For example, 
crosses between inbred strains of mice have led to the identification of several 
atherosclerotic quantitative trait loci (QTL) controlling strain-specific differences in diet-
induced atherosclerosis susceptibility.3,21 Likewise, valuable information about 
atherosclerotic modifiers has been obtained by studying crosses of Apoe–/– or Ldlr–/– mice 
with mice carrying other mutations.
The use of Apoe–/– and Ldlr–/– mice to develop an understanding of the genetic factors that 
modify atherogenesis provides the theme for this review. Other atherogenic mouse models 
and the effects of modifying genes related to lipid metabolism are well studied and have 
recently been reviewed.11–13,22 Consequently, in the present review, we consider how 
atherosclerosis is modified by 4 other variables: inflammation, disturbances in glucose 
metabolism, hypertension (HTN), and coagulation/fibrinolysis. These conditions are a 
source of continuous injurious stimuli that can trigger the early stages of atherosclerosis. We 
include several examples showing how the mouse has been used to test human 
polymorphisms as potential atherosclerotic modifiers based on prior epidemiological 
studies. Finally, we discuss some of the current limitations of mouse models of 
atherosclerosis and suggest where future improvements might be made.
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One approach to identifying modifiers of atherogenesis related to inflammation is to start 
from the knowledge that a product already implicated in inflammation occurs in a notable 
way in atherosclerotic plaques. For example, finding a specific cytokine in atherosclerotic 
plaques but not in normal vessels is circumstantial evidence that the cytokine may be 
involved in the pathogenesis of atherosclerosis, although this association does not reveal 
whether the molecule (1) reduces the atherogenic process, (2) accelerates it, or (3) is merely 
secondary to atherosclerosis. However, by using genetic or other manipulations to alter the 
level of the potentially important product, some discrimination among these alternatives is 
possible.
In 1993, Ross20 suggested in his landmark review that atherosclerosis can largely be viewed 
as a self-perpetuating inflammatory disease. Accordingly, we begin by considering the genes 
listed in Table 1 that are known to affect inflammation and that have been tested for 
involvement in atherogenesis by using Apoe–/– and/or Ldlr–/– mice. As Ross elaborated in 
his review, the atherosclerotic inflammatory response progresses in discrete stages, which 
are so characteristic that the presence of certain inflammatory cell types can be used to 
define the progression of atherosclerotic lesions.
In the early stages, the lesions are fatty streaks composed of lipid-rich macrophages. At this 
stage, molecules involved in leukocyte (and particularly, monocyte/macrophage) function, 
recruitment, rolling, adherence, transendothelial migration, and activation are likely to play 
key roles. The importance of monocytes/macrophages in the pathogenesis of atherosclerosis 
has been confirmed by experiments affecting molecules in these pathways. For example, 
osteopetrotic (op) mice have a mutation in the gene for macrophage colony stimulating 
factor (MCSF) that causes a severe decrease in the number of monocytes/macrophages in 
the mutant animals. ApoE-deficient mice crossed with op mice produce offspring that 
develop much smaller lesions than do control apoE-deficient mice.23 In fact, the absence of 
MCSF causes the single, largest decrease in lesion size of all of the genes that have been 
tested to date (Table 1, line 14). Importantly, there is a gene-dosage effect, as MCSF 
heterozygotes also have reduced lesions. Likewise, administration of an antibody against the 
receptor for MCSF reduces lesion size in apoE-deficient mice.24 Cell adhesion molecules 
that facilitate monocyte rolling and adherence also influence atherogenesis (see lines 10 to 
13 of Table 1),25–28 as do cytokines that affect monocyte recruitment and activation 
(reviewed in Reference 29). Monocyte chemoattractant protein-1 (MCP-1) is a cytokine that 
acts through its receptor, CC chemokine receptor 2 (CCR2), on monocytes, macrophages, 
and T lymphocytes. The absence of MCP-1 dramatically decreases lesion size in LDLR-
deficient mice30 (see line 1, Table 1). Similarly, the absence or decrease of CCR2 causes a 
reduction in lesion size in apoE-deficient mice31,32 (see lines 2 and 3, Table 1). In the 
opposite direction, irradiated Apoe–/– mice, in which the bone marrow has been replaced 
with cells that overexpress MCP-1, have an increased atherosclerotic lesion size33 (see line 
4, Table 1).
Although these alterations in the MCSF and MCP-1 pathways have marked effects on the 
progression of atherosclerosis, they do not completely eliminate macrophage-derived foam 
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cell development and fatty streak formation. Furthermore, the plaques in these mice still 
progress with time to more complex lesions. Additionally, although most of the evidence 
implicates macrophages as proatherosclerotic mediators, there is some evidence that they 
have some atheroprotective effects.34
The fatty streak progresses to intermediate lesions that contain monoclonal expansions of 
smooth muscle cells as well as increased numbers of macrophages and T cells. The potential 
role of T and B lymphocytes has been extensively evaluated, revealing a complex picture. 
Mice deficient in either recombinase-activating gene 1 or 2 (RAG1 or RAG2) do not 
produce functional T or B cells owing to a defect in V(D)J recombination. Experiments with 
Apoe–/– mice on a high-fat diet showed that the total absence of T and B cells caused by the 
absence of RAG1 or RAG2 did not affect lesion development.35,36 However, on a normal 
chow diet, Apoe–/– mice deficient in RAG1 have a modest decrease in lesion size compared 
with Apoe–/– controls (see Table 1, lines 15 and 16).35 The role of T cells in atherogenesis 
has been investigated by studying genetic alterations of the CD40-CD154 interaction37 or 
by the administration of antibodies against CD154.38 CD40, a cell surface receptor found on 
many immune cells, shares homology with tumor necrosis factor receptors. CD154, the 
ligand for CD40, is thought to be restricted to CD4+ T lymphocytes. When Ldlr–/– mice are 
fed a high-fat diet, treatment with antibodies to CD154 reduces expression of adhesion 
molecules and lesion size.37 Consistent with this observation, Apoe–/– mice that are also 
deficient in CD154 have a dramatic 5-fold decrease in lesion size, and the plaques in these 
mice also have a more stable, collagen-rich plaque phenotype with a reduced T cell/
macrophage content (see line 5, Table 1). Similar plaque phenotypes have been seen in mice 
lacking the interferon-g receptor (IFN-γR)39 (line 6, Table 1).
The small-molecule mediators of acute inflammation, such as histamine, prostaglandins, 
leukotrienes, and thromboxanes, have not been extensively studied as atherosclerotic 
modifiers despite the observation that some anti-inflammatory agents such as aspirin clearly 
reduce the risk of atherosclerotically mediated cardiac events.40,41 Two experiments are, 
however, relevant: disruption of the 12/15-lipoxygenase gene in Apoe–/– mice decreases 
atherosclerotic lesions,42 and transgenically overexpressing group IIa phospholipase A2 
(sPLA2) in C57BL/6 mice fed a high-fat diet increases lesion size.43 Thus, arachidonic acid 
metabolites have demonstrable effects on lesion development.
Although macrophages and T cells are important in atherogenesis, neutrophils appear to be 
less important. Neutrophils are not notable in atherosclerotic lesions, even in CCR2-
deficient, Apoe–/– mice, which have persistent neutrophilia in other tissues after 
inflammatory stimulation.44 The C-X-C chemokine receptor 2 (CXCR2) is the receptor for 
interleukin-8 and growth-regulated oncogene (GROα) and is predominantly, though not 
exclusively, expressed in neutrophils. Irradiated Ldlr–/– mice, whose bone marrow is 
replaced with cells lacking the mouse homolog to CXCR2, develop smaller lesions45 (see 
line 7, Table 1), indicating that this pathway is important in atherogenesis. However, as the 
authors suggest, the CXCR2 pathway may be enhancing atherogenesis by promoting 
monocyte adhesion, recruitment, and activation rather than through neutrophil actions.29,45
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In humans, hyperglycemia is a strong risk factor for atherosclerotic cardiovascular disease.
46 Patients with diabetes have a greater incidence of myocardial infarction (MI) and stroke,
47 and only part of the increased risk can be explained by their other risk factors such as 
HTN or hyperlipidemia.48 The mechanism behind these interacting effects is poorly 
understood and may be due to any number of factors, including mitogenic effects of 
hyperinsulinemia or endothelial cell dysfunction caused by hyperglycemia.49 Recent work 
with streptozocin-treated mouse models of atherosclerosis is shedding light on a possible 
mechanism of hyperglycemic vascular injury and particularly, on the role of advanced 
glycation end products (AGEs). AGEs are a by-product of hyperglycemia that result from 
the nonenzymatic glycation of proteins, followed by oxidation-mediated irreversible 
rearrangements.50 Interaction of AGEs with the receptor for AGEs (RAGE)51 induces 
several inflammatory markers52 that could increase atherosclerosis. Moderate 
hyperglycemia, achieved by giving supplemental insulin to streptozocintreated, cholesterol-
fed Ldlr–/– mice of mixed genetic background, did not increase atherosclerotic lesion size53 
(see Table 2, line 4). However, more fulminant hyperglycemia in streptozocin-treated, back-
crossed apoE-deficient mice resulted in large increases in plasma glucose and atherosclerotic 
lesion size54,55 (see Table 2, lines 1 and 2). The experiments of Park et al55 support the 
importance of AGEs by demonstrating that this increase in lesions could be suppressed in a 
dose-dependent manner by daily injections of the soluble receptor for advanced glycation 
end products (sRAGE), which acts as a molecular “sink” for AGEs (see Table 2, line 3). 
Whether all of the enhancement of atherosclerosis in diabetes can be explained by the AGEs 
will have to wait for further experiments. Efforts to understand the link between 
hyperglycemia and atherosclerosis will be greatly enhanced by the development of animal 
models with both sustained hyperglycemia and atherosclerosis solely due to genetic factors.
53,56
In humans and mice, diabetes is clearly a polygenic disorder,57–59 and although some 
chromosomal regions have been linked to diabetes, identification of the genes involved has 
proven difficult. New diabetic mouse models promise to change this situation. The insulin 
receptor (IR) is a receptor tyrosine kinase, and binding of insulin to the IR stimulates 
phosphorylation of insulin receptor substrates 1 and 2 (IRS-1 and IRS-2), which then 
activate other signaling molecules in the insulin signaling cascade. Mice homozygously 
deficient in either IR or IRS-2 die prematurely,60,61 whereas mice deficient in IRS-1 have 
severe growth retardation.62,63 In contrast, compound heterozygotes, which are 
heterozygous for a normal copy and a disrupted copy of IR, IRS-1, and/or IRS-2, survive 
and develop insulin-resistant diabetes.64,65 The insulin-responsive glucose transporter, 
GLUT4, is important in postprandial glucose metabolism as a facilitative transporter in 
skeletal muscle and adipose tissue. Mice heterozygous for disruption of GLUT4 develop 
hyperinsulinemia and hyperglycemia as they age.66 The phenotypes in these mice are 
complex, because both the IRS-1–deficient and GLUT4 heterozygous animals also have 
markedly elevated blood pressure.66,67 Nevertheless, exciting and informative results 
relating diabetes and atherosclerosis are likely to follow when these new diabetic models are 
combined with apoE or LDLR deficiencies.
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Interaction Between HTN and Atherosclerosis
HTN (defined as a blood pressure >140/90 mm Hg) and atherosclerosis are leading causes 
of morbidity and mortality in the developed world,68 and a considerable body of evidence 
suggests that HTN contributes to the development and progression of atherosclerosis. For 
instance, atherosclerosis occurs in high-pressure arteries but not in low-pressure veins, and 
lesions tend to be localized at areas of high wall stress.69 People with HTN are 3 times more 
likely to develop atherosclerosis than normotensive people,70 and antihypertensive 
treatment reduces the risk of death from atherosclerotically mediated cardiovascular events.
71,72 Complex genetics and confounding variables make the study of HTN plus 
atherosclerosis difficult in humans. In addition, proving a direct causal role for HTN in the 
pathogenesis of atherosclerosis is complicated by the powerful homeostatic mechanisms that 
control blood pressure. Thus, alterations in blood pressure invariably cause compensatory 
changes in various vasoactive mediators, and changes in these circulating vasoactive 
mediators not only affect blood pressure but also act locally to affect atherosclerosis. This 
makes it difficult to separate the mechanical effects of blood pressure in atherogenesis from 
the local effects of vasoactive mediators.
Many of the animal model studies of HTN plus atherosclerosis have been made by using 
surgical treatments to induce chronic coarctation of the abdominal aorta. Aortic constriction 
increases both the pressure and the lesions proximal to the constriction in 
hypercholesterolemic rabbits.73,74 Surgical constriction of the renal artery also increases 
atherosclerosis in rabbits.75 To date, these surgical approaches have not been applied to 
study HTN and atherogenesis in the mouse. Another approach has utilized drugs to raise or 
lower blood pressure.76 For instance, infusion of agents that increase blood pressure, like 
angiotensin II or NG-nitro-L-arginine methyl ester, increases atherosclerosis in some models,
77–79 whereas treatment of HTN with various antihypertensive drugs decreases 
atherosclerosis in several animal models (reviewed in Reference 76). Antihypertensive drug 
treatment studies in atherogenic mouse models have yielded conflicting data. Some studies 
have shown atheroprotective effects of antihypertension therapy without demonstrably 
lowering the blood pressure.80–82 However, in 1 of the most interesting studies, Makaritsis 
et al83 showed that neither a-adrenergic nor angiotensin receptor blockade alone lowered 
blood pressure or decreased lesions in Apoe–/– mice, but simultaneous blockade decreased 
both blood pressure and lesion size. Furthermore, we observed that chronic treatment with 
the angiotensin-converting enzyme (ACE) inhibitor enalapril did not significantly reduce 
atherosclerosis or lower the blood pressure of apoE-deficient mice, which are inherently 
normotensive.84
Currently, there are only a few genetic models with combined atherosclerosis and HTN. In 
one study, mice that express both a human renin transgene and a human angiotensinogen 
transgene were generated on a C57BL/6 genetic background. When fed a high-cholesterol 
diet, these mice have an elevated blood pressure (by 20 mm Hg) and develop larger lesions 
than equivalent nontransgenic mice.85 Recently, we have developed a genetic model in 
which HTN is combined with atherosclerosis by crossing apoE-deficient mice with 
endothelial nitric oxide synthase (eNOS–/–)–deficient mice.84 Similar results were obtained 
in eNOS–/–, Apoe–/– mice maintained on a high-fat diet.86 eNOS serves important basal 
Knowles and Maeda Page 6






















regulatory functions in the vasculature. In response to stimuli such as shear stress or 
acetylcholine, eNOS catalyzes the production of NO, which diffuses across the endothelial 
cell membrane into smooth muscle cells, inducing vasodilation. It also acts locally to 
prevent platelet and leukocyte adhesion.87 In comparison with the Apoe–/– controls, doubly 
deficient eNOS–/–, Apoe–/– mice are hypertensive (by 20 mm Hg), have atherosclerotic 
lesions twice the size, and also develop kidney damage (see Table 3, lines 1 and 2). These 
deleterious effects of eNOS deficiency were reduced by chronic treatment with enalapril at 
the same dose that was ineffective in Apoe–/– mice that were eNOS+/+ and had a normal 
blood pressure.84 These experiments are also notable because they demonstrate that in mice, 
the atheroprotective effects of enalapril are independent of NO production through eNOS 
and that a measurable component of increased atherosclerosis is due to an increase in blood 
pressure.
The distribution of atherosclerotic plaques appears to be different in eNOS–/– Apoe–/– mice 
than in Apoe–/– mice, potentially shedding light on one mechanism that may determine the 
localization of atheromas. Plaques develop in the descending and abdominal aortas of the 
double-knockout mice even by 4 months of age. In contrast, in apoE-deficient mice, lesions 
do not become prominent in these regions until 8 months of age. As previously mentioned, 
atherosclerotic plaques tend to develop in areas where blood flow is turbulent and where 
flow-induced shear stress is low but where pressure-induced vascular wall strain is high.
69,88,89 It is possible that normal eNOS function prevents the development of plaques in 
areas of high shear stress, so that an absence of eNOS leads to plaque development in these 
areas. Cross-breeding Apoe–/– or Ldlr–/– mice with other genetic models of HTN is 
desirable, because analysis with various antihypertensive treatments may clarify the 
causative link between increased blood pressure and enhanced atherosclerosis and perhaps 
identify better treatment strategies.
A powerful approach to confirm genes that modify the severity of atherosclerosis is to 
design experiments in mice to test whether gene polymorphisms identified in human 
epidemiological association studies actually affect atherosclerosis. There are many 
challenges in studying complex diseases such as atherosclerosis in humans. Not only are the 
environmental and genetic backgrounds of individuals diverse, but also there is a high 
likelihood that differences will occur in other unsuspected genes tightly linked to a candidate 
gene. Effects due to linked differences can therefore easily be misinterpreted as due to 
differences in the candidate gene. Well-designed experiments in mice can eliminate these 
complications, although only a few such tests have yet been done.
The human ACE gene provides an example. This gene has 2 common alleles, I and D, which 
differ by the presence (I)or absence (D) of an Alu sequence in intron 16. Individuals 
homozygous for the I allele have an ≈35% lower ACE activity than do individuals 
homozygous for the D allele.90 Several large studies have examined the frequencies of these 
ACE gene variants in case-control subjects for atherosclerosis or MI. Association of the ACE 
genotype with disease was found in some studies but not in others.91–93 We have therefore 
examined the effect of plasma ACE levels on diet-induced atherosclerosis by using Apoe-
heterozygous mice combined with 1 (±) or 2(+/+) copies of the Ace gene. The 2-copy 
animals have normal plasma ACE levels, whereas the 1-copy animals have half-normal 
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levels (the genetic equivalent of 50% inhibition by a converting-enzyme inhibitor). The mice 
were all from an F1 generation between C57BL/6 and 129 mice, so that their genetic 
backgrounds were completely identical except for their Ace gene status. The results showed 
that plasma ACE activity differences similar to those seen in humans did not lead to 
differences in blood pressure or in atherosclerotic lesion size. These results suggest that 
variation in the ACE gene in humans is unlikely to affect the development of atherosclerosis 
or HTN in humans (see Table 3, line 3).94,95
Coagulation, Fibrinolysis, and Atherosclerosis
In humans, blood clots and thromboses play a major role in the morbidity and mortality 
associated with cardiovascular disease.68 Most ischemic cardiovascular events are due to 
thrombotic occlusion, and the risk of MI and stroke is decreased by anticoagulant and 
fibrinolytic therapy. However, evidence that hemostatic pathways affect the development 
and progression of atherosclerosis is circumstantial. For example, elevated fibrinogen levels 
in plasma are a risk factor for cardiovascular disease,96 but it is not clear whether the 
elevated plasma fibrinogen enhances atherosclerosis or is a response to a chronic 
inflammatory condition, as fibrinogen is an acute-phase protein. To test whether reduced 
plasma fibrinogen levels alter the development of atherosclerosis, Xiao et al97 crossed 
fibrinogen-deficient mice to Apoe–/– mice on a 129/B6 mixed genetic background. In these 
mice, fibrinogen deficiency did not alter lesion size (see Table 3, line 4). In contrast, in mice 
that were more mildly atherosclerotic as a consequence of expressing an apo (a) transgene, 
fibrinogen deficiency decreased both atherosclerotic lesions and apo (a) accumulation in the 
vessel wall.98 The authors suggested that the high plasma cholesterol in Apoe–/– mice may 
have masked the smaller effect of fibrinogen deficiency.
Plasminogen activator inhibitor-1 (PAI-1) is another member of the fibrin/fibrinolytic 
pathway whose association with coronary heart disease has been extensively tested in 
humans, with mixed results.99–101 PAI-1 is the primary inhibitor of the conversion of 
plasminogen to plasmin. Plasminogen is a proenzyme that is converted to its active form, 
plasmin, by physiological activators such as tissue plasminogen activator and urokinase 
plasminogen activator. Plasmin-mediated proteolysis is critical to the dissolution of fibrin 
matrixes in arterial and venous thrombi. The balance between plasminogen activation/
inactivation may be critical in the development of atherosclerosis. A common polymorphism 
in the promoter region of the PAI-1 gene, which causes varied expression of the gene, is 
consequently a candidate for affecting atherosclerosis. Experiments by Sjoland et al102 in 
both Apoe- and Ldlr-deficient mice on a C57BL/6 background have shown that neither the 
absence of PAI-1 nor its overexpression by a transgene affects lesion development, 
suggesting that the levels of PAI-1 do not affect the development of atherosclerosis (see 
Table 3, lines 6 and 7). Nevertheless, the absence of plasminogen greatly increases 
atherosclerotic lesion size in Apoe–/– mice of a hybrid C57BL/6/NIH Black Swiss/129 
background103 (see Table 3, line 5). To reconcile these experiments, the authors proposed 
that alternative inhibitors of plasminogen activators may exist in mice, so that the effects of 
manipulating the PAI-1 locus are masked, or that the increased infectious complications that 
are present in plasminogen-null mice may affect the development of atherosclerosis.102
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A general caveat is required in determining causative links between gene mutations and 
atherosclerosis. Current evaluations of atherosclerosis in mice focus on the development of 
plaques and their progression to complex lesions. Plaque rupture and subsequent thrombosis, 
which precipitate clinical events like MI, are very rare in these mouse models and are only 
seen in extreme circumstances (eg, Apoe–/–-Ldlr–/– doubly mutant mice on a high-fat diet).
104 Consequently, although the ACE or PAI-1 polymorphisms do not affect plaque 
development in mice, as described above, their involvement in later stages of vascular 
disease cannot be excluded.
In evaluating causative links between gene mutations and atherosclerosis, the choice 
between Apoe–/– or Ldlr–/– mice is not of crucial importance, as there is no compelling 
evidence that either of these models is inherently better than the other. We have not found 
any examples in the literature in which the same gene, either overexpressed or knocked out 
in both Apoe-deficient and Ldlr-deficient mice, gives different results (see Table 1, lines 1 to 
3 and 10 and Table 3, lines 6 and 7). However, it is important that analyses of these mouse 
models be well controlled to ensure that the genetic backgrounds of the parental strains, in 
most cases C57BL/6 as opposed to 129, does not bias the results. Presently, this 
complication is avoided through repeated back-crossing to the C57BL/6 genetic background. 
Less rigorous studies use littermates to control for genetic variability, on the assumption that 
genetic differences not linked to the locus of interest will be randomly distributed among the 
offspring. However, if only a small number of littermates are used, nonrandom segregation 
of any nonlinked differences may bias the results. The effects of genes linked to the 
mutation are more difficult to eliminate unless other strict breeding strategies are employed 
(reviewed in References 11 and 105). Thus, special caution is necessary when multiple 
genetic alterations (often available only on a 129 genetic background) are combined and 
bred with an atherosclerotic model (often on a C57BL/6 genetic background). The situation 
is particularly difficult when the combined mutations cause decreased lesions, because every 
altered locus generated in 129 embryonic stem cells carries with it linked DNA from the 129 
strain, which is an atherosclerosis-resistant strain when compared with C57BL/6. A spurious 
decrease in lesion size is consequently more likely than a spurious increase in lesion size.
Atherosclerotic modifiers differ between mouse strains. Thus, plaque development caused 
by the absence of apoE is different on an FBV or a C3H genetic background compared with 
the C57BL/6 background.106,107 Also, a naturally occurring apoE deficiency in Mus 
musculus molossinius, with severe xanthomas and a shortened life span, was recently 
identified, but these mice have relatively small aortic plaques when compared with Apoe–/– 
mice on a C57BL/6 background.108 Identification of the loci that contribute to strain 
differences in atherosclerotic susceptibility will likely yield new candidates for human 
susceptibility, and Apoe–/– or Ldlr–/– mutations should accelerate their identification. 
Nevertheless, testing each gene effect on multiple genetic backgrounds by breeding is of 
borderline practicality. Regenerating interesting mutations such as Apoe–/– or Ldlr–/– by 
using embryonic stem cells from inbred strains other than 129 (such as atherosclerosis-
susceptible C57BL/6 mice or the less-susceptible strains DBA/1 or BALB/c) may prove 
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easier than the time-consuming, costly, and labor-intensive task of backcrossing to 
congenicity.
Further uses of gene targeting and transgenic mice assure that additional models of 
atherosclerosis will be developed. The development of mouse models in which plaque 
rupture occurs is particularly important, as discussed above. Also, the application of Cre-lox 
technology to develop tissue-specific and/or time-dependent knockouts109 will prove 
valuable for dissecting the mechanism of atherosclerosis, although such animals do not 
strictly represent inherited genetic variations, which are of course lifelong and affect 
multiple organ systems.
Finally, we emphasize that mouse knockout experiments are the genetic equivalent of 
recessively inherited conditions in humans due to the loss of gene function. This type of 
condition makes only a small contribution to the total human burden of atherosclerosis. The 
pattern of inheritance of atherosclerosis in humans is more compatible with susceptibility 
being due to combinations of small, quantitative changes in gene function, analogous to the 
situation that occurs in mice that are heterozygous for a gene modification. Thus, it is 
extremely important not only to study whether a complete absence of gene function affects 
atherosclerosis but also to determine whether quantitative changes in the expression of 
genes affect the condition. Genes that affect atherosclerosis in mice in the heterozygous state 
are probably the best candidate genes for being related to atherosclerosis susceptibility in 
humans. Thus, the study of heterozygotes is extremely important (for more on the 
importance of quantitative changes, see Reference 95).
Conclusions: “Mice to Humans” and “Humans to Mice”
Genes implicated in processes such as inflammation, hyperglycemia, HTN, or coagulation/
fibrinolysis that have also been shown to affect the development of atherosclerosis in mice 
need to be studied in human populations to look for alleles that may account for 
susceptibility. Experiments to identify such modifiers benefit greatly by being carried out in 
parallel in mice and humans. For example, a recent epidemiological study has shown that a 
polymorphism in the eNOS gene is a risk factor for coronary artery disease and MI,110 a 
finding that is supported by the relationship that we have found between eNOS deficiency 
and atherogenesis.84
Human polymorphisms shown to be associated with atherosclerosis should be tested for 
causation in mice. One way to carry out such tests is to “humanize” the mouse by generating 
animals that have the same allelic differences, such as single-nucleotide polymorphisms 
(SNPs), that occur in human populations. For example, the effects of a pair of SNP 
differences in the human APOE gene were evaluated in mice. The 3 common APOE alleles 
in the human population, APOE*2, APOE*3, and APOE*4, differ only in 2 coding 
nucleotides resulting in amino acid changes. Various population-based studies have 
suggested that these small differences influence lipid metabolism in humans.111 Recently, 
our laboratory used mice with a targeted replacement of the endogenous mouse allele with 
the different human alleles to show that protein structures coded by these alleles are 
responsible for plasma retention of lipoproteins and atherosclerosis susceptibility.112,113
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The effect of any single SNP is likely to be small. However, eventually it will be possible to 
combine many of these small variations in a single mouse. Comparing various 
“combinations” should yield important information about which combinations are 
particularly deleterious and which are protective. It is certainly not easy to breed these 
“compound” mutants. However, once “prototype” animals have been obtained, cloning via 
nuclear transfer is a potential future way to facilitate the generation of sufficient numbers of 
these animals to carry out meaningful studies.114,115
The ability to go back and forth between humans and mice, made possible by targeted 
mouse models, has and will continue to play an integral part in the study of atherosclerosis. 
The pathogenesis of atherosclerosis is complex, polygenic, and multifactorial. Knowledge of 
the genetic determinants of atherosclerosis, aided by mouse studies, will allow us to identify 
disease-prone persons and design specific preventive measures for them and treatments 
tailored for those for whom prevention is no longer an option.
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